A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine

Nicholas C Wu, Seth J Zost, Andrew J Thompson, David Oyen, Corwin M Nycholat, Ryan McBride, James C Paulson, Scott E Hensley, Ian A Wilson, Nicholas C Wu, Seth J Zost, Andrew J Thompson, David Oyen, Corwin M Nycholat, Ryan McBride, James C Paulson, Scott E Hensley, Ian A Wilson

Abstract

The effectiveness of the annual influenza vaccine has declined in recent years, especially for the H3N2 component, and is a concern for global public health. A major cause for this lack in effectiveness has been attributed to the egg-based vaccine production process. Substitutions on the hemagglutinin glycoprotein (HA) often arise during virus passaging that change its antigenicity and hence vaccine effectiveness. Here, we characterize the effect of a prevalent substitution, L194P, in egg-passaged H3N2 viruses. X-ray structural analysis reveals that this substitution surprisingly increases the mobility of the 190-helix and neighboring regions in antigenic site B, which forms one side of the receptor binding site (RBS) and is immunodominant in recent human H3N2 viruses. Importantly, the L194P substitution decreases binding and neutralization by an RBS-targeted broadly neutralizing antibody by three orders of magnitude and significantly changes the HA antigenicity as measured by binding of human serum antibodies. The receptor binding mode and specificity are also altered to adapt to avian receptors during egg passaging. Overall, these findings help explain the low effectiveness of the seasonal vaccine against H3N2 viruses, and suggest that alternative approaches should be accelerated for producing influenza vaccines as well as isolating clinical isolates.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. L194P is an egg-adaptive substitution…
Fig 1. L194P is an egg-adaptive substitution in human H3N2 HA.
(A) Frequency of different amino acids observed at HA residue 194 of human H3N2 isolates. Egg: isolates that were sequenced after passaging in egg. Unpassaged: isolates that were sequenced without passaging. (B) Egg-passaged human H3N2 isolates are categorized based on the number of passage. The fractions of isolates in different number of passage that possess a Pro at residue 194 are shown. Error bars represent the standard error estimated from a binomial distribution. (C) Frequency of different amino acids observed at HA residue 194 of pandemic H1N1 (“swine influenza”) human isolates. Egg: isolates that were sequenced after passaging in egg. Unpassaged: isolates that were sequenced without passaging. Of note, no sequence information was found for unpassaged isolates in 2013. (D) Cα traces of the HA structures of Bris07 P194 (blue) and L194 (green) are aligned and compared.
Fig 2. B -value analysis of Bris07…
Fig 2. B-value analysis of Bris07 HA.
(A-B)B-values (Å2) of Cα atoms in (A) Bris07 P194 and (B) Bris07 L194 are projected on the HA structure. Of note, on average, the B-values of Cα atoms in Bris07 P194 (mean ± s.d. = 58 ± 24 Å2) are lower than that of Bris07 L194 (mean ± s.d. = 64 ± 24 Å2). (C) The normalized B-values of Cα atoms in Bris07 P194 (blue) and L194 (green) are compared. The bottom panel shows their difference in HA1: (normalized B-values of Cα atoms in P194)–(normalized B-values of Cα atoms in L194). The amino-acid position is plotted along the x-axis. Positions corresponding to the residues (Res) of interest are shaded in grey.
Fig 3. Impact of L194P substitution on…
Fig 3. Impact of L194P substitution on antigenicity.
(A) The difference in normalized B-values between Bris07 P194 and Bris07 L194 (B-value Diff.) for each Cα atom is projected on the HA structure of Bris07 L194. B-value Diff. = (normalized B-values of Cα atoms in P194)–(normalized B-values of Cα atoms in L194). (B-C) Biolayer interferometry (BLI) was used to measure the binding kinetics of C05 IgG against the recombinant HA proteins of (B) Bris07 P194 and (C) Bris07 L194. (D) HAI assay of C05 IgG against Bris07 P194 and Bris07 L194 viruses. Duplicates were performed for each of Bris07 P194 and L194.
Fig 4. Vaccines elicit antibodies in humans…
Fig 4. Vaccines elicit antibodies in humans that poorly react to HA with the L194P mutation.
Sera from 21 human donors were collected before (A) and after (B) vaccination with the 2015–2016 influenza vaccine. Antibody binding to virus-like particles expressing WT and L194P HA was measured using ELISA. Titer is expressed as the dilution of sera required to reach a fixed absorbance (O.D. = 0.75). The geometric mean ELISA titers calculated after testing each sera sample in triplicate are shown. Significance was determined using a paired Student’s t-test.
Fig 5. Crystal structures of Bris07 P194…
Fig 5. Crystal structures of Bris07 P194 and L194 HAs in complex with receptor analogs.
HA structures of (A) Bris07 P194 in complex with 3'SLNLN, (B) Bris07 L194 in complex with 3'SLNLN, (C) Bris07 P194 in complex with 6'SLNLN, and (D) Bris07 L194 in complex with 6'SLNLN are shown. The apo form for each structure is aligned and colored in grey. Glycan receptor analogs (3'SLNLN and 6'SLNLN) are colored in yellow and shown as stick representations. Hydrogen bonds are represented by black dashed lines.

References

    1. Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature. 1981;289(5796):373–8. .
    1. Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M, Wilson IA, et al. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci U S A. 1984;81(6):1779–83. ; PubMed Central PMCID: PMCPMC345004.
    1. Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem. 1987;56:365–94. doi: .
    1. Wu NC, Young AP, Al-Mawsawi LQ, Olson CA, Feng J, Qi H, et al. High-throughput profiling of influenza A virus hemagglutinin gene at single-nucleotide resolution. Sci Rep. 2014;4:4942 doi: ; PubMed Central PMCID: PMCPMC4018626.
    1. Thyagarajan B, Bloom JD. The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin. eLife. 2014;3:e03300 doi: ; PubMed Central PMCID: PMCPMC4109307.
    1. Hajj Hussein I, Chams N, Chams S, El Sayegh S, Badran R, Raad M, et al. Vaccines through centuries: major cornerstones of global health. Front Public Health. 2015;3:269 doi: ; PubMed Central PMCID: PMCPMC4659912.
    1. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36–44. doi: .
    1. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942–51. doi: .
    1. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012–13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014;9(3):e92153 doi: ; PubMed Central PMCID: PMCPMC3965421.
    1. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Euro Surveill. 2015;20(4). .
    1. Ito T, Suzuki Y, Takada A, Kawamoto A, Otsuki K, Masuda H, et al. Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J Virol. 1997;71(4):3357–62. ; PubMed Central PMCID: PMCPMC191479.
    1. Sriwilaijaroen N, Kondo S, Yagi H, Wilairat P, Hiramatsu H, Ito M, et al. Analysis of N-glycans in embryonated chicken egg chorioallantoic and amniotic cells responsible for binding and adaptation of human and avian influenza viruses. Glycoconj J. 2009;26(4):433–43. doi: .
    1. Rogers GN, Daniels RS, Skehel JJ, Wiley DC, Wang XF, Higa HH, et al. Host-mediated selection of influenza virus receptor variants. Sialic acid-α2,6Gal-specific clones of A/duck/Ukraine/1/63 revert to sialic acid-α2,3Gal-specific wild type in ovo. J Biol Chem. 1985;260(12):7362–7. .
    1. Gambaryan AS, Tuzikov AB, Piskarev VE, Yamnikova SS, Lvov DK, Robertson JS, et al. Specification of receptor-binding phenotypes of influenza virus isolates from different hosts using synthetic sialylglycopolymers: non-egg-adapted human H1 and H3 influenza A and influenza B viruses share a common high binding affinity for 6'-sialyl(N-acetyllactosamine). Virology. 1997;232(2):345–50. doi: .
    1. Gambaryan AS, Karasin AI, Tuzikov AB, Chinarev AA, Pazynina GV, Bovin NV, et al. Receptor-binding properties of swine influenza viruses isolated and propagated in MDCK cells. Virus Res. 2005;114(1–2):15–22. doi: .
    1. Robertson JS, Nicolson C, Major D, Robertson EW, Wood JM. The role of amniotic passage in the egg-adaptation of human influenza virus is revealed by haemagglutinin sequence analyses. J Gen Virol. 1993;74((Pt 10)):2047–51. doi: .
    1. Robertson JS, Bootman JS, Newman R, Oxford JS, Daniels RS, Webster RG, et al. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. Virology. 1987;160(1):31–7. .
    1. Kodihalli S, Justewicz DM, Gubareva LV, Webster RG. Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective. J Virol. 1995;69(8):4888–97. ; PubMed Central PMCID: PMCPMC189303.
    1. Chen Z, Zhou H, Jin H. The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response. Vaccine. 2010;28(24):4079–85. doi: .
    1. Popova L, Smith K, West AH, Wilson PC, James JA, Thompson LF, et al. Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. PLoS One. 2012;7(7):e41895 doi: ; PubMed Central PMCID: PMCPMC3405050.
    1. Parker L, Wharton SA, Martin SR, Cross K, Lin Y, Liu Y, et al. Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses. J Gen Virol. 2016;97(6):1333–44. doi: .
    1. Raymond DD, Stewart SM, Lee J, Ferdman J, Bajic G, Do KT, et al. Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nat Med. 2016;22(12):1465–9. doi: .
    1. Hartgroves LC, Koudstaal W, McLeod C, Moncorge O, Thompson CI, Ellis J, et al. Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs. Vaccine. 2010;28(17):2973–9. doi: .
    1. Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? J Virol. 2010;84(13):6769–81. doi: ; PubMed Central PMCID: PMCPMC2903250.
    1. Stevens J, Chen LM, Carney PJ, Garten R, Foust A, Le J, et al. Receptor specificity of influenza A H3N2 viruses isolated in mammalian cells and embryonated chicken eggs. J Virol. 2010;84(16):8287–99. doi: ; PubMed Central PMCID: PMCPMC2916524.
    1. Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, Khayat R, et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature. 2012;489(7417):526–32. doi: ; PubMed Central PMCID: PMCPMC3538848.
    1. Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014–2015 influenza season. Cell Rep. 2015;12(1):1–6. doi: ; PubMed Central PMCID: PMCPMC4487778.
    1. Shi Y, Wu Y, Zhang W, Qi J, Gao GF. Enabling the 'host jump': structural determinants of receptor-binding specificity in influenza A viruses. Nat Rev Microbiol. 2014;12(12):822–31. doi: .
    1. Xiong X, Coombs PJ, Martin SR, Liu J, Xiao H, McCauley JW, et al. Receptor binding by a ferret-transmissible H5 avian influenza virus. Nature. 2013;497(7449):392–6. doi: .
    1. Sabesan S, Bock K, Paulson JC. Conformational analysis of sialyloligosaccharides. Carbohydr Res. 1991;218:27–54. .
    1. Asensio JL, Arda A, Canada FJ, Jimenez-Barbero J. Carbohydrate-aromatic interactions. Acc Chem Res. 2013;46(4):946–54. doi: .
    1. Lin YP, Xiong X, Wharton SA, Martin SR, Coombs PJ, Vachieri SG, et al. Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc Natl Acad Sci U S A. 2012;109(52):21474–9. doi: ; PubMed Central PMCID: PMCPMC3535595.
    1. Xu R, McBride R, Paulson JC, Basler CF, Wilson IA. Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J Virol. 2010;84(4):1715–21. doi: ; PubMed Central PMCID: PMCPMC2812380.
    1. Stevens J, Blixt O, Glaser L, Taubenberger JK, Palese P, Paulson JC, et al. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol. 2006;355(5):1143–55. doi: .
    1. Peng W, de Vries RP, Grant OC, Thompson AJ, McBride R, Tsogtbaatar B, et al. Recent H3N2 viruses have evolved specificity for extended, branched human-type receptors, conferring potential for Increased avidity. Cell Host Microbe. 2017;21:1–12.
    1. Meisner J, Szretter KJ, Bradley KC, Langley WA, Li ZN, Lee BJ, et al. Infectivity studies of influenza virus hemagglutinin receptor binding site mutants in mice. J Virol. 2008;82(10):5079–83. doi: ; PubMed Central PMCID: PMCPMC2346734.
    1. Martin J, Wharton SA, Lin YP, Takemoto DK, Skehel JJ, Wiley DC, et al. Studies of the binding properties of influenza hemagglutinin receptor-site mutants. Virology. 1998;241(1):101–11. .
    1. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 2002;420(6916):678–82. doi: .
    1. MacRaild CA, Zachrdla M, Andrew D, Krishnarjuna B, Novacek J, Zidek L, et al. Conformational dynamics and antigenicity in the disordered malaria antigen merozoite surface protein 2. PLoS One. 2015;10(3):e0119899 doi: ; PubMed Central PMCID: PMCPMC4351039.
    1. Kong L, Lee DE, Kadam RU, Liu T, Giang E, Nieusma T, et al. Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen. Proc Natl Acad Sci U S A. 2016;113(45):12768–73. doi: ; PubMed Central PMCID: PMCPMC5111675.
    1. Milian E, Kamen AA. Current and emerging cell culture manufacturing technologies for influenza vaccines. Biomed Res Int. 2015;2015:504831 doi: ; PubMed Central PMCID: PMCPMC4359798.
    1. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol. 2013;30(4):772–80. doi: ; PubMed Central PMCID: PMCPMC3603318.
    1. McWhite CD, Meyer AG, Wilke CO. Sequence amplification via cell passaging creates spurious signals of positive adaptation in influenza virus H3N2 hemagglutinin. Virus Evol. 2016;2(2):vew026 doi: ; PubMed Central PMCID: PMCPMC5049878.
    1. Otwinowski Z, Minor W. Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307–26. doi:
    1. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40(Pt 4):658–74. doi: ; PubMed Central PMCID: PMCPMC2483472.
    1. Lee PS, Ohshima N, Stanfield RL, Yu W, Iba Y, Okuno Y, et al. Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus. Nat Commun. 2014;5:3614 doi: ; PubMed Central PMCID: PMCPMC4358779.
    1. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 4):486–501. doi: ; PubMed Central PMCID: PMCPMC2852313.
    1. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr. 2011;67(Pt 4):355–67. doi: ; PubMed Central PMCID: PMCPMC3069751.
    1. Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 1):12–21. doi: ; PubMed Central PMCID: PMCPMC2803126.
    1. Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput. 2015;11(8):3696–713. doi: ; PubMed Central PMCID: PMCPMC4821407.
    1. Kirschner KN, Yongye AB, Tschampel SM, Gonzalez-Outeirino J, Daniels CR, Foley BL, et al. GLYCAM06: a generalizable biomolecular force field. Carbohydrates. J Comput Chem. 2008;29(4):622–55. doi: ; PubMed Central PMCID: PMCPMC4423547.
    1. Horn HW, Swope WC, Pitera JW, Madura JD, Dick TJ, Hura GL, et al. Development of an improved four-site water model for biomolecular simulations: TIP4P-Ew. J Chem Phys. 2004;120(20):9665–78. doi: .
    1. Case DA, Betz RM, Cerutti DS, Cheatham I, T. E., Darden TA, Duke RE, et al. AMBER 2016. University of California, San Francisco.
    1. Hopkins CW, Le Grand S, Walker RC, Roitberg AE. Long-time-step molecular dynamics through hydrogen mass repartitioning. J Chem Theory Comput. 2015;11(4):1864–74. doi: .
    1. Roe DR, Cheatham TE 3rd. PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput. 2013;9(7):3084–95. doi: .
    1. Yuan Z, Zhao J, Wang ZX. Flexibility analysis of enzyme active sites by crystallographic temperature factors. Protein Eng. 2003;16(2):109–14. .
    1. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A. 1999;96(16):9345–50. ; PubMed Central PMCID: PMCPMC17785.
    1. Ha Y, Stevens DJ, Skehel JJ, Wiley DC. H5 avian and H9 swine influenza virus haemagglutinin structures: possible origin of influenza subtypes. EMBO J. 2002;21(5):865–75. doi: ; PubMed Central PMCID: PMCPMC125880.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner